Adaptimmune looks to salvage ovarian cancer study by adding fludarabine to prep patients
The use of fludarabine was fingered as a key culprit in the deaths of several patients taking Juno’s lead CAR-T therapy, but it’s an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
